Gonadotrophin-releasing hormone antagonist regimen versus agonist regimen among normal ovarian responders: a systematic review and meta-analysis

Jiajie Lai, Jing Lu, Xiuling Wu, Xuemei Chen

Abstract

This systematic review and meta-analysis compared the efficacy and safety of gonadotrophin-releasing hormone antagonist (GnRH-ant) versus GnRH agonist (GnRH-a) regimens in women with a normal ovarian response undergoing controlled ovarian stimulation. PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang were searched from inception to April 30, 2024. Randomized controlled trials were independently screened, appraised for risk of bias, and synthesized using meta-analysis. Eight RCTs involving 1,841 participants were included. Compared with GnRH-a, GnRH-ant was associated with fewer retrieved oocytes (WMD −0.77, 95% CI −1.35 to −0.20; P=0.009) and a lower implantation rate (RR 0.75, 95% CI 0.60 to 0.93; P=0.009), but required less total gonadotrophin (WMD −389.65; P<0.001) and a shorter stimulation duration (WMD −2.00 days; P<0.001). GnRH-ant reduced the risk of ovarian hyperstimulation syndrome (OHSS) (RR 0.33, 95% CI 0.11 to 0.94; P=0.037). Clinical pregnancy (RR 0.84, P=0.056) and abortion rates (RR 1.13, P=0.729) were comparable. Taken together, GnRH-ant reduced gonadotrophin exposure, shortened stimulation, and lowered OHSS risk, but produced slightly fewer oocytes and a lower implantation rate; clinical pregnancy and abortion rates did not differ significantly between regimens.

Full Text:

PDF

References

Chen ZJ, Liu JY, Huang HF, Qiao J, Zhou CQ, Huang GN, et al. Guidelines for Infertility Diagnosis. Chinese Journal of Obstetrics and Gynecology, 2019;54(8):505-11.

Vander Borght M , Wyns C. Fertility and infertility: Definition and epidemiology, Clinical Biochemistry, 2018;62:2-10. https://doi.org/10.1016/j.clinbiochem.2018.03.012

Cao J. [The adverse effects and the related mechanisms of environmental exposure on male reproductive health], Zhonghua Yu Fang Yi Xue Za Zhi, 2018;52(7):681-4. https://doi.org/10.3760/cma.j.issn.0253-9624.2018.07.001

Liu YJ, Sun XL, Wu YL, Zong SY, Liu KH, Ma ZF, et al. New advances in the treatment of infertility. Chinese Journal of Clinical Rational Drug Use, 2014;(16):196-7.

Esteves SC, Humaidan P, Roque M , Agarwal A. Female infertility and assisted reproductive technology, Panminerva Medica, 2019;61(1):1-2. https://doi.org/10.23736/S0031-0808.18.03553-X

Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist, Fertility and Sterility, 2002;78(5):1068-72. https://doi.org/10.1016/s0015-0282(02)03374-5

Qiao J, Ma CH, Liu JY, Ma X, Li SW, Yang YZ, et al. A consensus of poor ovarian response. Chinese Journal of Reproduction and Contraception, 2015;35(4):211-23.

Orvieto R , Patrizio P. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate, Reproductive Biomedicine Online, 2013;26(1):4-8. https://doi.org/10.1016/j.rbmo.2012.11.001

Association ECWGotRMPCotCWsM. Expert consensus on standardized application of antagonist protocol in assisted reproductive technology. Chinese Journal of Reproduction and Contraception, 2022;42(2):109-16.

Xing W, Lin H, Li Y, Yang D, Wang W , Zhang Q. Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI? PLoS One, 2015;10(10):e0140286. https://doi.org/10.1371/journal.pone.0140286

Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, Kunicki M, Marca AL, Lainas G, Clef NL, Massin N, Mastenbroek S, Polyzos N, Sunkara SK, Timeva T, Toyli M, Urbancsek J, Vermeulen N , Broekmans F. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI, Human Reproduction Open, 2020;2020(4):hoaa067. https://doi.org/10.1093/hropen/hoaa067

Wang R, Lin S, Wang Y, Qian W , Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis, PLoS One, 2017;12(4):e0175985. https://doi.org/10.1371/journal.pone.0175985

Hu LL, Huang GL, Sun HX, Fan LQ, Feng Y, Shen H, et al. CSRM consensus on key indicators for quality control in ART clinical operation. Journal of Reproductive Medicine, 2018;27(9):828-35.

Zeng XT, Bao CP, Cao SY , Liu JY. Meta-analysis Series No. 3: Quality Evaluation Tools for Randomized Controlled Trials. Chinese Journal of Evidence-Bases Cardiovascular Medicine, 2012;4(03):183-5.

Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, Witjes H, Heijnen E , Mannaerts B. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates, Gynecological Endocrinology, 2012;28(10):800-4. https://doi.org/10.3109/09513590.2012.665103

Xu B, Geerts D, Hu S, Yue J, Li Z, Zhu G , Jin L. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study, Human Reproduction, 2020;35(6):1306-18. https://doi.org/10.1093/humrep/deaa086

Tian LF, Wu XW, Xia LZ, Wu QF, Chen J, Xu DF, et al. Comparison of clinical outcomes between an early follicular phase prolonged protocol and a GnRH-antagonist protocol in vitro fertilization-embryo transfer in infertile patients with normal ovarian reserve. Jiangxi Medical Journal, 2020;55(10):1354-8,76.

Chen XX, Deng AM, Li SZ, Lu XY , Liang XM. Influence of two GnRH analogues upon early embryo development in vitro fertilizationembryo transfer. International Medicine and Health Guidance News, 2011;17(20):2486-90.

Guan WZ ,Wang XX. Comparison of the effectiveness between gonadotropin-releasing hormone antagonist protocol and gonadotropin-releasing hormone agonist long protocol in patients older than 35 years old with normal ovarian response. Practical Pharmacy and Clinical Remedies, 2018;21(10):1166-9.

Fang L, Guo L , Huang Y. Observation on the Application of GnRHA regimen and GnRHa Long Regimen in IVT-ET Treatment. Shandong Medical Journal, 2012;52(18):82-3.

Zhang F. Comparison of the effects of GnRH antagonist fixation and flexible regimens and GnRH agonist long regimens on IVF treatment for patients with normal ovarian response. Yiyao Qianyan, 2021;11(11):22-4.

Shuai M , Wu QF. Comparison of the application of long-acting long protocol and antagonist protocol in the early follicular phase in the population with normal ovarian response. Journal of Gannan Medical University, 2020;40(6):554-7.

Deng YF, Mo D, Fen Y, Ma WH , Yang YH. Comparison of IVF/ICSI-ET outcomes between luteal phase long protocol and GnRH antagonist protocol in patients with unexplained infertility. Journal of Reproductive Medicine, 2023;32(11):1615-22.

Li T, Liu X, Yang X, Wang N, Wang Y, Li W, Liang X ,Huang R. Comparison of the efficacy of depot GnRH agonist protocol and the GnRH antagonist protocol in patients with repeated IVF failure: a retrospective cohort study, Human Fertility, 2023;26(5):1299-306. https://doi.org/10.1080/14647273.2023.2175267

Chen JL, Liu SY, Li L, Chen GW, Zhang X ,Sun XX. Efficacy comparison of GnRH antagonist protocol and GnRH long protocol for the patients undergoing fresh embryo transfer. Chinese Journal of Clinical Medicine, 2017;24(03):339-42.

Zhou C, Sun Q, Cheng Q, Li HR, Yao B , Chen L. The ovulation-inducing treatments of young patients in POSEIDON groups. Journal of Medical Research & Combat Trauma Care, 2020;33(09):948-51.

Zhang J, Sun Y, Xu Y, Shi B, Han Y, Luo Z, Zhao Z, Hao G ,Gao B. Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol, Frontiers in Endocrinology, 2021;12:578783. https://doi.org/10.3389/fendo.2021.578783

Kang WW and Liang XX. Application of growth hormone injection in luteal phase in IVF-ET assisted pregnancy in aged infertile patients with diminished ovarian reserve. Hainan Medical Journal, 2020;31(07):875-8.

Ma YC, Jiao YQ, Zhang SC, Gao X, Yang HJ ,Song CM. Effects of Controlled Ovarian Hyperstimulation on the Endometrium. Progress in Physiological Sciences, 2024;55(01):86-90.

Deng BB, Wang WJ, Li RQ, Huang LL, Zhang NF, Qu SB, et al. Comparison of different stimulation protocols for patients receiving in vitro fertilization after poor ovarian response. Chinese Journal of Biomedical Engineering, 2013;19(1):32-8.

Fu Z, Liu L, Huang HY , Yang M. Comparison of the application effects of different ovulation induction methods on in vitro fertilization-embryo transfer in PCOS patients. Chinese Journal of Woman and Child Health Research, 2022;33(4):98-103.

Tehraninejad E, Ghahghaei Nezamabadi A, Rashidi B, Sohrabi M, Bagheri M, Haghollahi F, Azimi Nekoo E , Jafarabadi M. GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran, Iran J Reprod Med, 2011;9(3):171-6.

Xiao J, Su C , Zeng X. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis, PLoS One, 2014;9(9):e106854. https://doi.org/10.1371/journal.pone.0106854

Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F , van Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type, Human Reproduction Update, 2017;23(5):560-79. https://doi.org/10.1093/humupd/dmx017

Yang R, Guan Y, Perrot V, Ma J , Li R. Comparison of the Long-Acting GnRH Agonist Follicular Protocol with the GnRH Antagonist Protocol in Women Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis, Advances in Therapy, 2021;38(5):2027-37. https://doi.org/10.1007/s12325-020-01612-7

Tan XQ, Qiu Y , Huang Y. GnRH antagonists are applied in in vitro fertilization-embryo transfer for patients with polycystic ovary syndrome. Journal of Guangxi Medical University, 2013;30(4):558-61.

Xiao JS, Su CM , Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in normal ovarian responders undergone IVF: a systematic review and meta-analysis. Journal of Reproductive Medicine, 2015;24(10):834-44.

Xia M , Zheng J. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders, BMC Pregnancy and Childbirth, 2021;21(1):372. https://doi.org/10.1186/s12884-021-03849-8

Xu Y, Zhang Y, Zhu D, Zhai X, Wu F , Wang A. Influence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles, Biomedical Reports, 2019;10(2):113-8. https://doi.org/10.3892/br.2018.1176

Deng K, Li L, Wang YN, Zhou K ,Sun XL. Comparison of effectiveness and safety of GnRH agonist long protocol with GnRH antagonist protocol in Chinese infertile women: a systematic review and meta-analysis. Chinese Journal of Reproduction and Contraception, 2022;42(5):490-502.

Ruan M, Fang L, Yang S, Chen Z, Wu Y, Qu X, Zhao J, Cheng J. Prolonged pituitary downregulation with gonadotropin-releasing hormone agonist improves the live-birth rate: a retrospective cohort study comparing 3 different protocols, Annals of Palliative Medicine, 2021;10(9):9984-92. https://doi.org/10.21037/apm-21-2335

Fang JY ,Hao CF. Influence of GnRH agonist down-regulation on clinical outcomes of frozen-thawed embryo transfer cycle in younger patients with diminished ovarian reserve. Journal of Reproductive Medicine, 2020;29(02):209-13.

Zhao D, Xie R , Li X. Comparison of pregnancy outcome after fresh embryo transfer between GnRH antagonist and GnRH agonist regimens in patients with thin endometrium, Frontiers in Medicine, 2023;10:1071014. https://doi.org/10.3389/fmed.2023.1071014

Xiao J, Chang S ,Chen S. The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis, Fertility and Sterility, 2013;100(6):1594-601. https://doi.org/10.1016/j.fertnstert.2013.08.024

Refbacks

  • There are currently no refbacks.